AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9669786 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (n = 582)
Number of subjects: 1168
Study 7915090 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.08 mg/kg
Number of subjects: 30
Study 7915090 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 0.08 mg/kg
Number of subjects: 30
Study 3242978 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 8
Study 3242978 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin D2 (PGD2)
Number of subjects: 8
Study 3242978 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 alpha,11 beta-PGF2
Number of subjects: 8
Study 3242978 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of histamine and PGD2
Number of subjects: 8
Study 3242978 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 8
Study 29861026 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation group (six weeks of mindfulness meditation, four to five times per week)
Number of subjects: 100
Study 29861026 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation group (female meditators)
Number of subjects: 100
Study 29861026 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched experiential activity with no meditation component)
Number of subjects: 100
Study 29261503 — intervention group
Group type: EXPERIMENTAL
Intervention: Training package including contraceptive technology update and interventions to improve counseling and clinical skills and business practices
Number of subjects: 965
Study 29261503 — intervention group
Group type: EXPERIMENTAL
Intervention: Training package
Number of subjects: 965
Study 29261503 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 965
Study 25369726 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 301
Study 25369726 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 301
Study 25369726 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin and Tolterodine
Number of subjects: 301
Study 23168303 — intervention group
Group type: EXPERIMENTAL
Intervention: Child- and parent-focused developmental care (5 sessions)
Number of subjects: 178
Study 23168303 — intervention group
Group type: COMPARATOR
Intervention: Standard child-focused developmental care (5 sessions)
Number of subjects: 178
Study 21681697 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional 5-Fluorouracil combined with topical silicone
Number of subjects: 50
Study 21681697 — intervention group
Group type: COMPARATOR
Intervention: Perilesional surgical excision of keloids combined with topical silicone
Number of subjects: 50
Study 18505169 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4+ T-cell count-guided use of ART (Drug Conservation arm; DC)
Number of subjects: 5472
Study 18505169 — intervention group
Group type: COMPARATOR
Intervention: Continuous ART (Viral Suppression arm; VS)
Number of subjects: 5472
Study 16783561 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 800 mg daily for 6 days
Number of subjects: 19
Study 16783561 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg daily for 6 days
Number of subjects: 19
Study 16783561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 14666027 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (100 mg/kg into cardiopulmonary bypass prime followed by infusion at 20 mg.kg(‐1).h(‐1), n = 20)
Number of subjects: 40
Study 14666027 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 40
Study 10844878 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodox treatment (Version A)
Number of subjects: 398
Study 10844878 — intervention group
Group type: COMPARATOR
Intervention: Unconventional treatment (Version B)
Number of subjects: 398
Study 8857435 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgastric, pulsed Doppler echocardiography
Number of subjects: 30
Study 8857435 — intervention group
Group type: COMPARATOR
Intervention: Thermodilution (TD)
Number of subjects: 30
Study 1739873 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin (50 U on alternate days for 2 weeks monthly) + Calcium (500 mg/day)
Number of subjects: 45
Study 1739873 — intervention group
Group type: COMPARATOR
Intervention: Calcitonin (50 U on alternate days for 2 weeks monthly) + Calcium (500 mg/day) + Phosphate (750 mg/day)
Number of subjects: 45
Study 1739873 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin (50 U on alternate days for 2 weeks monthly) + Calcium (500 mg/day) + Norandrostenolone decanoate (50 mg/month)
Number of subjects: 45
Study 6149531 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate
Number of subjects: 200
Study 6149531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 31362736 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispensing practices for anti-malarials
Number of subjects: 230
Study 31362736 — intervention group
Group type: COMPARATOR
Intervention: Experience of dispensers
Number of subjects: 230
Study 29869556 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 0
Study 29869556 — intervention group
Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 0
Study 27089235 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive relationship education program
Number of subjects: 20
Study 27089235 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 20
Study 24750172 — intervention group
Group type: EXPERIMENTAL
Intervention: Teenage pregnancy prevention program
Number of subjects: 816
Study 23137504 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous CRT
Number of subjects: 238
Study 23137504 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized CRT
Number of subjects: 238
Study 19304567 — intervention group
Group type: EXPERIMENTAL
Intervention: hylan G-F 20
Number of subjects: 253
Study 19304567 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 253
Study 18565275 — intervention group
Group type: EXPERIMENTAL
Intervention: l-tetrahydropalmatine (l-THP)
Number of subjects: 120
Study 18565275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 15377573 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine physiotherapy
Number of subjects: 286
Study 15377573 — intervention group
Group type: COMPARATOR
Intervention: Advice on remaining active from a physiotherapist
Number of subjects: 286
Study 11686540 — intervention group
Group type: EXPERIMENTAL
Intervention: First-degree relatives of individuals with Type 2 diabetes
Number of subjects: 235
Study 11686540 — intervention group
Group type: COMPARATOR
Intervention: Non-relatives
Number of subjects: 235
Study 9672449 — intervention group
Group type: COMPARATOR
Intervention: Plain lidocaine
Number of subjects: 20
Study 9672449 — intervention group
Group type: COMPARATOR
Intervention: Warmed lidocaine
Number of subjects: 20
Study 9672449 — intervention group
Group type: COMPARATOR
Intervention: Buffered lidocaine
Number of subjects: 20
Study 9672449 — intervention group
Group type: COMPARATOR
Intervention: Warmed, buffered lidocaine
Number of subjects: 20
Study 7544041 — intervention group
Group type: EXPERIMENTAL
Intervention: Teflon-coated catheters
Number of subjects: 0
Study 7544041 — intervention group
Group type: COMPARATOR
Intervention: Latex-coated catheters
Number of subjects: 0
Study 7544041 — intervention group
Group type: COMPARATOR
Intervention: Silicone-coated catheters
Number of subjects: 0
Study 2686340 — intervention group
Group type: EXPERIMENTAL
Intervention: Enisoprost (prostaglandin E1 analogue) at doses of 10, 25, 50, 100, 200, or 400 micrograms
Number of subjects: 48
Study 2686340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 792865 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflucortolone valerate (ointment)
Number of subjects: 27
Study 29083225 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodily movement
Number of subjects: 43
Study 29083225 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipping
Number of subjects: 43
Study 29083225 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated group)
Number of subjects: 43
Study 27219235 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Aponeurotomy and Lipofilling (PALF)
Number of subjects: 80
Study 27219235 — intervention group
Group type: COMPARATOR
Intervention: Limited Fasciectomy
Number of subjects: 80
Study 24674235 — intervention group
Group type: EXPERIMENTAL
Intervention: Full voucher-based CM intervention
Number of subjects: 131
Study 24674235 — intervention group
Group type: COMPARATOR
Intervention: Lite voucher-based CM intervention
Number of subjects: 131
Study 22253016 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-sparing group (OR-SP), n = 24
Number of subjects: 48
Study 22253016 — intervention group
Group type: COMPARATOR
Intervention: Oral-unsparing group (OR-USP), n = 24
Number of subjects: 48
Study 22253016 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-sparing group (OR-SP)
Number of subjects: 48
Study 22253016 — intervention group
Group type: COMPARATOR
Intervention: Oral-unsparing group (OR-USP)
Number of subjects: 48
Study 20551644 — intervention group
Group type: EXPERIMENTAL
Intervention: FeSO(4) gel (1 mmol/l FeSO(4))
Number of subjects: 10
Study 20551644 — intervention group
Group type: EXPERIMENTAL
Intervention: F gel (NaF 1.23%)
Number of subjects: 10
Study 20551644 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (negative control)
Number of subjects: 10
Study 18792100 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV test at rlu ratio cutoff 1.00
Number of subjects: 18438
Study 18792100 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV test at rlu ratio cutoff 3.00
Number of subjects: 18438
Study 18792100 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV test at rlu ratio cutoff 10.00
Number of subjects: 18438
Study 18792100 — intervention group
Group type: COMPARATOR
Intervention: Conventional cytology
Number of subjects: 18438
Study 16180954 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical practice
Number of subjects: 24
Study 16180954 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental practice
Number of subjects: 24
Study 16180954 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 12520146 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting balloon (n=30)
Number of subjects: 61
Study 12520146 — intervention group
Group type: COMPARATOR
Intervention: Stenting alone (n=31)
Number of subjects: 61
Study 10978853 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB supplementation (3.0 g HMB/d)
Number of subjects: 75
Study 10978853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 8791019 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine monotherapy
Number of subjects: 59
Study 8791019 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine combined with levodopa
Number of subjects: 59
Study 1636394 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sodium cromoglycate eyedrops
Number of subjects: 68
Study 1636394 — intervention group
Group type: COMPARATOR
Intervention: terfenadine
Number of subjects: 68
Study 6148005 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 333
Study 6148005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study 6148005 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study (nonblack patients)
Number of subjects: 333
Study 30716550 — intervention group
Group type: EXPERIMENTAL
Intervention: EHS plus ABC (Attachment and Biobehavioral Catch-up)
Number of subjects: 153
Study 30716550 — intervention group
Group type: COMPARATOR
Intervention: Control group (home-based EHS plus 10 weekly books)
Number of subjects: 153
Study 30121640 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU bolus
Number of subjects: 132
Study 30121640 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU continuous infusion
Number of subjects: 132
Study 30121640 — intervention group
Group type: COMPARATOR
Intervention: Control group (no 5-FU)
Number of subjects: 132
Study 26830380 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned cesarean delivery
Number of subjects: 4603
Study 26830380 — intervention group
Group type: COMPARATOR
Intervention: Planned vaginal delivery
Number of subjects: 4603
Study 24780501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 507
Study 24780501 — intervention group
Group type: EXPERIMENTAL
Intervention: CER-001 3 mg/kg
Number of subjects: 507
Study 24780501 — intervention group
Group type: EXPERIMENTAL
Intervention: CER-001 6 mg/kg
Number of subjects: 507
Study 24780501 — intervention group
Group type: EXPERIMENTAL
Intervention: CER-001 12 mg/kg
Number of subjects: 507
Study 24780501 — intervention group
Group type: EXPERIMENTAL
Intervention: Major cardiovascular events
Number of subjects: 507
Study 22836250 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone and Yohimbine (combined administration)
Number of subjects: 0
Study 22836250 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone alone
Number of subjects: 0
Study 22836250 — intervention group
Group type: COMPARATOR
Intervention: Yohimbine alone
Number of subjects: 0
Study 20308693 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (4.5 mg/kg)
Number of subjects: 15
Study 20308693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 17902094 — intervention group
Group type: EXPERIMENTAL
Intervention: High oral carbohydrate (CHO) beverage (125 mg/ml)
Number of subjects: 12
Study 17902094 — intervention group
Group type: COMPARATOR
Intervention: Low oral carbohydrate (CHO) beverage (25 mg/ml)
Number of subjects: 12
Study 16096241 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational training programme plus psychosomatic treatment
Number of subjects: 266
Study 16096241 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (control)
Number of subjects: 266
Study 11911556 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprinkle-dose regimen of 60-mg MSER capsule on applesauce
Number of subjects: 30
Study 11911556 — intervention group
Group type: COMPARATOR
Intervention: Intact 60-mg MSER capsule swallowed whole
Number of subjects: 30
Study 10382080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine delivery system releasing progesterone (IDS-P)
Number of subjects: 0
Study 10382080 — intervention group
Group type: COMPARATOR
Intervention: No IDS-P (control)
Number of subjects: 0
Study 7697274 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy
Number of subjects: 20
Study 7697274 — intervention group
Group type: EXPERIMENTAL
Intervention: Mite immunotherapy
Number of subjects: 20
Study 3606850 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle aspiration alone
Number of subjects: 62
Study 3606850 — intervention group
Group type: COMPARATOR
Intervention: Incision and drainage
Number of subjects: 62
Study 29945905 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV-Physical training
Number of subjects: 47
Study 29945905 — intervention group
Group type: COMPARATOR
Intervention: Physical training alone
Number of subjects: 47
Study 26612407 — intervention group
Group type: EXPERIMENTAL
Intervention: EAS regimen (esomeprazole 20 mg b.i.d., amoxicillin 500 mg q.i.d., sitafloxacin 100 mg b.i.d.)
Number of subjects: 80
Study 26612407 — intervention group
Group type: EXPERIMENTAL
Intervention: EMS regimen (esomeprazole 20 mg b.i.d., metronidazole 250 mg b.i.d., sitafloxacin 100 mg b.i.d.)
Number of subjects: 80
Study 26612407 — intervention group
Group type: COMPARATOR
Intervention: Both EAS and EMS regimens
Number of subjects: 80
Study 24402559 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 249
Study 24402559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 23550916 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide/timolol FC
Number of subjects: 50
Study 23550916 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine/timolol FC
Number of subjects: 50
Study 23550916 — intervention group
Group type: COMPARATOR
Intervention: Both adjunctive FC therapies
Number of subjects: 50
Study 20584056 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve replacement (AVR)
Number of subjects: 27
Study 20584056 — intervention group
Group type: COMPARATOR
Intervention: Control group (17 subjects without known cardiac disease)
Number of subjects: 27
Study 18412989 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of bone turnover (e.g., serum bone alkaline phosphatase, total osteocalcin, procollagen type I N-terminal propeptide)
Number of subjects: 0
Study 18412989 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiresorptive therapy (e.g., hormone-replacement therapy, raloxifene, bisphosphonates)
Number of subjects: 0
Study 18412989 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional interventions
Number of subjects: 0
Study 18412989 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone turnover markers
Number of subjects: 0
Study 20064989 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium dichloroisocyanurate (NaDCC) tablets
Number of subjects: 240
Study 20064989 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 240
Study 16263979 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual sugar administration (SG) - 2.5 g of sugar under the tongue, with subgroups of 0.1 g/kg, 0.15 g/kg, and 0.2 g/kg
Number of subjects: 69
Study 16263979 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dextrose administration (IG) - 8 mL of 30% dextrose in a single bolus
Number of subjects: 69
Study 16263979 — intervention group
Group type: COMPARATOR
Intervention: Oral sugar administration (OG) - 2.5 g of sugar
Number of subjects: 69
Study 16263979 — intervention group
Group type: COMPARATOR
Intervention: Water administration (C)
Number of subjects: 69
Study 11187414 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (group meetings and individual counseling focused on dietary change, physical activity, and social support)
Number of subjects: 1191
Study 11187414 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 1191
Study 11187414 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 1191
Study 11187414 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (subgroup analysis)
Number of subjects: 1191
Study 9536540 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% fusidic acid lotion (Fucidin lotion)
Number of subjects: 52
Study 9536540 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 52
Study 7906472 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.5% timolol
Number of subjects: 57
Study 3300313 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg orally twice daily)
Number of subjects: 104
Study 3300313 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole
Number of subjects: 104
Study 3300313 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 104
Study 11837758 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose glucocorticoid pulse therapy (GPT)
Number of subjects: 102
Study 11837758 — intervention group
Group type: COMPARATOR
Intervention: No glucocorticoid pulse therapy (Control)
Number of subjects: 102
Study 31481504 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (R) at 375 mg/m2 weekly for 4 weeks and Ipilimumab (I) at 3 mg/kg on day 1 and every 3 weeks for four doses
Number of subjects: 33
Study 31481504 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (R) with Ipilimumab (I)
Number of subjects: 33
Study 31481504 — intervention group
Group type: COMPARATOR
Intervention: R with I delayed 2 weeks
Number of subjects: 33
Study 29172945 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational acellular pertussis vaccines (aP) containing pertussis antigens PT, FHA, and PRN at different dosages
Number of subjects: 420
Study 29172945 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational TdaP vaccines (containing TT and DT)
Number of subjects: 420
Study 29172945 — intervention group
Group type: COMPARATOR
Intervention: Licensed TdaP comparator containing chemically inactivated PT
Number of subjects: 420
Study 29172945 — intervention group
Group type: EXPERIMENTAL
Intervention: All investigational study formulations
Number of subjects: 420
Study 29172945 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational aP4 group
Number of subjects: 420
Study 27329896 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel fiber post group
Number of subjects: 53
Study 27329896 — intervention group
Group type: EXPERIMENTAL
Intervention: Double taper fiber post group
Number of subjects: 53
Study 27329896 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 53
Study 25455692 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine (up to 16 mg/24 h)
Number of subjects: 420
Study 25455692 — intervention group
Group type: COMPARATOR
Intervention: Ropinirole (up to 15 mg/day)
Number of subjects: 420
Study 25455692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 25455692 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 420
Study 25455692 — intervention group
Group type: COMPARATOR
Intervention: Ropinirole
Number of subjects: 420
Study 21950653 — intervention group
Group type: COMPARATOR
Intervention: CONTROLS
Number of subjects: 55
Study 21950653 — intervention group
Group type: EXPERIMENTAL
Intervention: RELATIVES
Number of subjects: 55
Study 21950653 — intervention group
Group type: EXPERIMENTAL
Intervention: IGT
Number of subjects: 55
Study 21950653 — intervention group
Group type: EXPERIMENTAL
Intervention: DMA
Number of subjects: 55
Study 21950653 — intervention group
Group type: EXPERIMENTAL
Intervention: DMB
Number of subjects: 55
Study 20092848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative fragment retrieval (group 1)
Number of subjects: 60
Study 20092848 — intervention group
Group type: COMPARATOR
Intervention: Exhaustive lithotripsy and spontaneous fragment expulsion (group 2)
Number of subjects: 60
Study 17391350 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood episode or symptoms, borderline/antisocial personality disorder, male gender, living alone, hypnotic drug, drugs for physical illness
Number of subjects: 253
Study 17391350 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypomanic symptoms
Number of subjects: 253